depletion

Teneliximab (Chi220) is a chimeric monoclonal antibody and a tumor necrosis factor receptor superfamily member 5 (CD40) inhibitor that blocks CD40-CD40L interactions.Teneliximab exerts partial agonist activity through CD40 and peripheral B-cell depletion, and may be used to study organ transplant rejection and rheumatoid arthritis.

Benralizumab (MEDI-563) is a monoclonal antibody targeting the interleukin-5 receptor alpha (IL-5Rα). It enhances antibody-dependent cell-mediated cytotoxicity, leading to a rapid depletion of eosinophils. Benralizumab is used for severe eosinophilic asthma and can be employed to prevent exacerbations of chronic obstructive pulmonary disease.

Quilizumab, a humanized IgG1κ monoclonal antibody also known as Anti-Human NGcGM3 Recombinant Antibody, specifically targets the M1-prime segment of membrane-expressed IgE. This action leads to the depletion of IgE-switched and memory B cells. Quilizumab shows potential in asthma research [1].

Dargistotug (M-6223) is a fully human IgG1 monoclonal antibody that targets TIGIT (T cell immune receptor with Ig domain and ITIM), an inhibitory immune checkpoint responsible for NK cell depletion and diminished cytokine secretion via interaction with CD155. It also modulates effector T cell activity and increases regulatory T cell (Tregs) function, contributing to immunosuppression [1].

Alemtuzumab is a humanized monoclonal antibody against CD52 an antigen found on the surface of normal and malignant lymphocytes.